A One-Time CRISPR Edit Cut LDL by Half—And It Kept Working a Year Later

Key takeaways

• A single intravenous CRISPR treatment designed to switch off the liver gene ANGPTL3 produced large, still-present reductions in LDL cholesterol and triglycerides one year later. At the highest dose, LDL fell by 52.5% and triglycerides by 47.8%.

• The intervention is designed as a permanent edit in liver cells, rather than a medication that must be taken daily or weekly.

• This was a first-in-human Phase 1 study in just 15 people. It is an important proof of concept—not a finished treatment or a result ready for broad use.

• The central idea is striking: a single molecular intervention may be able to reset a blood-lipid pathway for years, perhaps indefinitely.

Most approaches to improving LDL cholesterol and triglycerides rely on ongoing treatment. The effect lasts only as long as the intervention does: stop taking the medication, and the underlying biology resumes its prior pattern.

CTX310 is built around a different proposition. It delivers CRISPR-Cas9 gene-editing machinery to the liver, where it disrupts a gene called ANGPTL3. One infusion is intended to change how liver cells regulate circulating fats at the source.

In this early trial, the signal lasted. After one year, participants receiving the highest dose had average LDL reductions of 52.5% and triglyceride reductions of 47.8% from baseline.

Why ANGPTL3 matters

ANGPTL3 is a liver-produced protein that helps regulate the movement and processing of fats in the bloodstream. Reducing its activity has been associated with lower levels of LDL cholesterol and triglycerides.

The appeal of gene editing is not simply that it lowers a biomarker. It is that it could potentially establish a durable new baseline without requiring constant adherence, refills, injections, or the variability that comes with long-term routines.

That prospect matters for anyone who thinks of cardiometabolic markers as long-range inputs rather than isolated lab values. LDL and triglycerides reflect processes that compound across decades; reducing their cumulative exposure is one of the more direct ways to think about preserving vascular function over time.

Durability is the headline

The original early results showed a substantial reduction at two months. The newly reported one-year data matter because durability is the entire premise of a one-time gene edit.

The study also reported no serious treatment-related adverse events during the year of follow-up. But one year is not enough time to settle the safety question for an irreversible intervention. Participants are expected to remain under long-term observation for 15 years, consistent with regulatory expectations for gene-editing therapies.

The tradeoff

A durable intervention is also a less reversible one. With a conventional therapy, dose changes, pauses, or discontinuation remain options. A genomic edit in liver cells is meant to persist.

That makes the safety bar fundamentally different. Researchers will need much larger studies, longer follow-up, and careful assessment of editing precision, immune effects, liver outcomes, and the consequences of maintaining low ANGPTL3 activity over many years.

The takeaway

CTX310 is an early glimpse of a shift from managing blood markers continuously to editing an upstream control point once. The initial magnitude and one-year persistence are notable, but this was a 15-person, Phase 1 study supported by the therapy’s developer.

For now, this belongs in the category of technology to watch—not something to pursue. The bigger implication is that future prevention may increasingly involve durable biological “resets,” with interventions evaluated not only by how much they move a number, but by how safely they sustain that change across decades.

Reference:
Laffin LJ, Nicholls SJ, Scott RS, et al. Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310. New England Journal of Medicine. 2026. doi:10.1056/NEJMc2609825.